Sanyou Bio Congratulates Eluminex Biosciences and Foreseen Biotechnology on Major Achievements in Drug Innovation
Saturday, July 27, 2024
Eluminex Biosciences has revealed that their tri-specific fusion antibody drug, EB-105, has been administered for the first time to a patient with diabetic macular edema in the United States. This clinical trial, known as LOTUS, is an open-label, multicenter, single-dose, dose-escalation study delivered via intravitreal injection, and is being conducted across four hospitals in the U.S.
Foreseen Biotechnology announced an exclusive global licensing agreement for their ADC-targeted drug, FS001, with Ipsen Pharma SAS of France. Ipsen now has the exclusive rights to develop, manufacture, and commercialize FS001 on a global scale. The licensing deal includes a total payment of US$1.03 billion, which covers upfront payments, milestone payments, and sales royalties.
Eluminex Biosciences' preclinical studies indicate that EB-105 effectively inhibits key signal transduction pathways, including VEGF-A/VEGFR-2, Ang-2/Tie-2, and IL-6/IL-6R. By targeting both vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2), and disrupting inflammation-related pathways, EB-105 may offer enhanced therapeutic benefits for diabetic retinopathy patients compared to existing treatments.
Foreseen Biotechnology's FS001, based on a newly identified tumor-associated antigen, demonstrates high specificity and effective targeting. The drug features an innovative, stable cleavable linker and is combined with a potent topoisomerase I inhibitor, showing promising results in preclinical tests against drug-resistant cancer models.
Sanyou Bio was instrumental in supporting the discovery efforts of both Eluminex Biosciences and Foreseen Biotechnology.
Sanyou Bio, stated, "We are proud to have supported Eluminex Biosciences and Foreseen Biotechnology in their development of groundbreaking biologic drugs. We look forward to their continued success in research and development, and hope their innovations achieve clinical milestones that will benefit patients globally."
Source: prnewswire.com
